Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Washington University School of Medicine, St. Louis, Missouri, United States



Survival: 24.0 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: St. Louis, Missouri
   
Hospital: Washington University School of Medicine
   
Journal: Link
   
Date: 9/2010

Description:
Patients:
This phase 2 study involved 79 men with castrate-resistant prostate cancer. The median age of the group was 69 years.

Treatment:
Patients in this study were given a combination of two chemotherapy agents, docetaxel and estramustine, and a biologic therapy agent bevacizumab, which is an antibody the blocks a protein involved in cancer cell growth.

Toxicities:
There were 3 deaths related to treatment reported in this study. Causes included infection and thrombosis. Grade 3 and 4 neutropenia, leukopenia, fatigue, and pain were also reported.

Results:
The reported median progression-free survival in this study was 8 months. The median overall survival was 24 months.

Support:
This study was partially supported by Sanofi-Aventis and Genentech, makers of docetaxel and bevacizumab, respectively.

Correspondence: Dr. Joel Picus; email: picus@im.wustl.edu

E-mail to a Friend Email Physician More Information